Drugs / Cendakimab
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05638282 | Feb → Jun 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05175352 | Jun 2022 → Oct 2024 | eosinophilic esophagitis | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05337345 | May → Dec 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04373187 | Jun 2020 → May 2021 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04096105 | Oct 2019 → Jan 2020 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00986037 | Oct 2009 → Jul 2010 | asthma | AbbVie | Completed | No outcome recorded |
| Phase 22 trials · 2 met primary | ||||||
| Phase 2 | NCT04800315 | May 2021 → Jul 2022 | atopic eczema | Celgene Corporation | Completed | Met primary |
| Phase 2 | NCT02098473 | Aug 2014 → Feb 2016 | eosinophilic esophagitis | Celgene Corporation | Completed | Met primary |
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT04991935 | Aug 2022 → Aug 2025 | eosinophilic esophagitis | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05214768 | Mar 2022 → Jul 2024 | eosinophilic gastroenteritis | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT04753697 | Feb 2021 → Jan 2024 | eosinophilic esophagitis | Celgene Corporation | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-26 | Bristol-Myers Squibb | Results Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 bms.com ↗
Today, the company is announcing that the Phase 3 trial evaluating the efficacy and safety of cendakimab in patients with eosinophilic esophagitis (EoE) met both co-primary endpoints. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-07-26 | Bristol-Myers Squibb | Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 bms.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cendakimab | “In a phase 2 study, cendakimab, a recombinant, humanized anti-IL-13 monoclonal antibody, significantly reduced mean esophageal eosinophil counts and improved other inflammatory...” PMID 39384067 ↗ Oct 2024 |
| Known as | ABT-308 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00986037 ↗ |
| Known as | CC-93538 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04991935 ↗ |
| Known as | RPC4046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02098473 ↗ |
| Action | Inhibit | “prevents its binding to the receptor subunits IL13RA1 and IL13RA2” PMID 30395812 ↗ Nov 2018 |
| Modality | Monoclonal antibody | “RPC4046, a recombinant humanized monoclonal antibody against IL13” PMID 30395812 ↗ Nov 2018 |
| Route | Intravenous | “intravenous (IV) infusion only once at first dose” NCT02098473 ↗ |
| Target | IL13 | “RPC4046, a recombinant humanized monoclonal antibody against IL13” PMID 30395812 ↗ Nov 2018 |